Scientific Advisory Board

George Siber, M.D.	Executive Chairman
Darren Higgins, Ph.D.	Scientific Co-Founder; Professor of Microbiology and Molecular Genetics, Harvard Medical School
David Bernstein, M.D., M.A.	Albert Sabin Professor of Pediatrics, Cincinnati Children's Hospital
Robert Coffman, Ph.D.	Vice President and Chief Scientific Officer, Dynavax Technologies
Patrice Dubois, Ph.D.	Consultant, ImmunoVac Consulting
Robert Finberg, M.D.	Chairman, Department of Medicine, University of Massachussetts Medical School
Penny J. Hitchcock, D.V.M.	The Tauri Group; Former Chief of Sexually Transmitted Diseases Branch, NIAID, NIH
Peter Kiener, D.Phil.	President and CEO of Zyngenia
Adel Mahmoud, M.D., Ph.D.	Professor, Princeton University; Former President, Merck Vaccines
Richard Malley, M.D.	Assistant Professor of Pediatrics, Children's Hospital Boston and Harvard Medical School

George Siber, M.D.

Executive Chairman

Dr. Siber, most recently Executive Vice President and Chief Scientific Officer of Wyeth Vaccines, is a leading authority on vaccines. While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines, including Prevnar®, a pneumococcal vaccine which has achieved multibillion dollar revenues; Acel-Imune®, an acellular pertussis vaccine; and Meningitec®, a meningococcal meningitis vaccine. Prior to Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber led the research and manufacturing of multiple vaccines and immune globulins including Respigam®, a human immune globulin against respiratory syncytial virus.

Darren Higgins, Ph.D.

Scientific Co-Founder; Professor of Microbiology and Molecular Genetics, Harvard Medical School

Dr. Higgins laboratory at Harvard is focused on understanding fundamental host-pathogen interactions that lead to virulence and the development of protective immunity to intracellular bacterial pathogens. He has published in Science, Nature, and Nature Biotechnology. Dr. Higgins serves as an Editorial Board Member of the Journal of Bacteriology, and Infection and Immunity and has recently led projects on antigen delivery for the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases. He performed his post-doctoral work with Dr. Daniel Portnoy at the University of California at Berkeley and holds a Ph.D. in Microbiology and Immunology from the University of Michigan at Ann Arbor.

David Bernstein, M.D., M.A.

Albert Sabin Professor of Pediatrics, Cincinnati Children's Hospital

Dr. Bernstein, who also serves as director of the hospital's Division of Infectious Diseases, directs one of eight National Institutes of Health-funded Vaccine Evaluation Units. He has expertise in vaccines and antivirals against herpes simplex virus and cytomegalovirus and he was instrumental in the development of the precursor to the rotavirus vaccine Rotarix®. Dr. Bernstein has published over 200 manuscripts and book chapters on infectious diseases, vaccines, and antiviral drugs.

Robert Coffman, Ph.D.

Vice President and Chief Scientific Officer, Dynavax Technologies

Dr. Coffman, a member of the National Academy of Sciences, has made fundamental discoveries about the regulation of immune responses in allergic and infectious diseases. He shared the William S. Coley Award for Research in Immunology for discovery of the Th1 and Th2 subsets of T lymphocytes. Prior to joining Dynavax in 2000, Dr. Coffman served at the DNAX Research Institute for 19 years, most recently as Distinguished Research Fellow. Previously, he was a post-doctoral fellow at Stanford University Medical School. Dr. Coffman received his Ph.D. from the University of California, San Diego and his A.B. from Indiana University.

Patrice Dubois, Ph.D.

Consultant, ImmunoVac Consulting

Dr. Dubois is an expert on vaccine development and adjuvants. His current work includes participation in the Global Adjuvant Development Initiative at the University of Lausanne. He was previously with SmithKline Beecham (now Glaxo SmithKline), where he worked on the mode of action of adjuvants to evaluate vaccine-induced T cell responses.

Robert Finberg, M.D.

Chairman, Department of Medicine, University of Massachussetts Medical School

Dr. Finberg is internationally known for his work over the past 30 years on host responses to infections and treatment of immuno-compromised patients. Previously, he was Professor of Medicine at Harvard Medical School and Chief of the Infectious Disease Program at the Dana-Farber Cancer Institute in Boston. Dr. Finberg is also Chair of the Department of Medicine at UMass Memorial Healthcare. Dr. Finberg trained in Immunology with Dr. Baruj Benacerraf at Harvard Medical School and is an expert on T-cell responses to viruses and bacteria.

Penny J. Hitchcock, D.V.M.

The Tauri Group; Former Chief of Sexually Transmitted Diseases Branch, NIAID, NIH

Dr. Hitchcock's expertise spans infectious disease, public health, and biosecurity. Prior to the Tauri Group consulting firm, she has held positions at the National Institutes of Health as Chief of the Sexually Transmitted Diseases (STDs) Program, the University of Pittsburgh Medical Center's Center for Biosecurity as a Senior Associate, and the Los Alamos National Laboratory as a technical staff member and group leader. In recognition of her leadership and advocacy for STD research, Dr. Hitchcock was awarded the American Sexually Transmitted Diseases Association's Achievement Award in 2001.

Peter Kiener, D.Phil.

President and CEO of Zyngenia

Dr. Kiener has been a senior executive and researcher in biological therapeutics and drug development for more than 26 years. Before founding Zyngenia, which develops next generation antibody therapeutics, he served as Executive Vice President and Head of Research and Development at MedImmune, and following its acquisition by AstraZeneca, as Executive Vice President and Head of Biologics R&D. Prior to MedImmune, he held senior research positions at Bristol Myers Squibb. Dr. Kiener has published more than 100 papers in peer-reviewed journals, and is an inventor on more than 20 patents and patent applications.

Adel Mahmoud, M.D., Ph.D.

Professor, Princeton University; Former President, Merck Vaccines

Dr. Mahmound has had a distinguished career in industry and academia in the areas of vaccines and global infectious disease control. He currently has appointments at Princeton University's Woodrow Wilson School of Public and International Affairs and in the university's Department of Molecular Biology. Dr. Mahmoud was the President of Merck Vaccines from 1999 through 2005. At Merck, Dr. Mahmoud oversaw the company's extensive vaccine portfolio, including its HIV vaccine program; new vaccines for rotavirus (Rotateq®), human papillomavirus (Gardasil®), and shingles (Zostavax®); and a new combination vaccine for measles, mumps, rubella, and varicella (Proquad®).

Prior to joining Merck, Dr. Mahmoud was chairman of medicine and physician-in-chief at Case Western Reserve University and University Hospitals of Cleveland (1987-1998), and chief of geographic medicine (1977-1987). He is past President of the International Society for Infectious Diseases and former chair of the Board of Scientific Counselors of the U.S. National Center for Infectious Diseases. Dr. Mahmoud received his medical degree from the University of Cairo. He received his doctorate at the University of London, School of Hygiene and Tropical Medicine.

Richard Malley, M.D.

Assistant Professor of Pediatrics, Children's Hospital Boston and Harvard Medical School

Dr. Malley is an expert in infectious diseases in children, and pneumococcal research. For more than a decade, he has focused on pneumococcal-related acquired and innate immunity, correlates of protection, and mechanisms of protection from mucosal colonization. He is a co-discoverer of a cellular immune pathway, Th17, for protecting against mucosal colonization that is the basis for Genocea's S. pneumoniae vaccine program. Dr. Malley has published over 40 peer-reviewed research articles in the field of infectious diseases and vaccines.